Sanofi experienced a significant reduction in its market value, shedding $13 billion due to disappointing trial results for its eczema drug, causing a 10% drop in its share price. Its experimental drug, amlitelimab, met all primary and key secondary endpoints in the COAST 1 phase 3 study, but has been seen as a setback by the market due to its lower efficacy compared to Dupixent, Sanofi's existing eczema drug. Sanofi's CEO highlighted the importance of both IQ and EQ in the development and progression of the company, especially in light of potential advancements in AI. Amidst these trials, FDA approved Sanofi’s Wayrilz for Chronic Immune Thrombocytopenia and saw ease in advancing biosimilar approval process as well. Thermo Fisher Scientific completed acquisition of Sanofi’s site in Ridgefield, New Jersey. Furthermore, Sanofi's stock may experience some pressure as the anticipated efficacy of amlitelimab falls below expectations. However, amid setbacks, Deutsche Bank upgraded Sanofi to “buy”, setting target price at €110 based on Amlitelimab outlook. In addition to its developments in eczema treatments, Sanofi has also received FDA approval for Wayrilz to treat chronic ITP.
Sanofi News Analytics from Thu, 03 Apr 2025 20:10:10 GMT to Sat, 06 Sep 2025 19:10:33 GMT -
Rating -5
- Innovation 3
- Information 7
- Rumor -2
